Skip to main content

Matthew Waitkus

Assistant Professor in Neurosurgery
Neurosurgery
DUMC 2600, 203 Research Drive, Room 155, Durham, NC 27710
203 Research Drive, Durham, NC 27705

Overview


The Waitkus Laboratory is a team of researchers focused on understanding the molecular biology of malignant brain tumors. We work alongside clinician-scientists in the Preston Robert Tisch Brain Tumor Center at Duke to investigate the mechanisms by which brain tumors arise, progress, and recur. 

Adult and pediatric malignant gliomas are caused by specific sets of genetic mutations that allow tumor cells to (1) proliferate indefinitely, (2) obtain and utilize nutrients to grow, and (3) evade …

Current Appointments & Affiliations


Assistant Professor in Neurosurgery · 2021 - Present Neurosurgery, Neurosurgery
Assistant Professor of Pathology · 2021 - Present Pathology, Clinical Science Departments
Member of the Duke Cancer Institute · 2020 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.

Journal Article Neuro Oncol · June 3, 2024 A majority of cancers (~85%) activate the enzyme telomerase to maintain telomere length over multiple rounds of cellular division. Telomerase-negative cancers activate a distinct, telomerase-independent mechanism of telomere maintenance termed alternative ... Full text Link to item Cite

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Journal Article Nat Commun · January 25, 2024 Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. ... Full text Link to item Cite

Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma.

Journal Article J Clin Invest · January 16, 2024 Since the discovery that cGAS/STING recognizes endogenous DNA released from dying cancer cells and induces type I interferon and antitumor T cell responses, efforts to understand and therapeutically target the STING pathway in cancer have ensued. Relative ... Full text Link to item Cite
View All Publications

Recent Grants


Role of ATRX deficiency as a determinant of topoisomerase 1 inhibitor sensitivity in high grade gliomas

ResearchPrincipal Investigator · Awarded by American Cancer Society, Inc. · 2025 - 2028

The Role of SMARCAL1 Depletion on Increased Immunogenicity in ALT+ Gliomas

FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2028

ATRXmutations,innate immune activation and therapeutic vunerabilityin malignant gliomas

ResearchInvestigator · Awarded by National Cancer Institute · 2022 - 2027

View All Grants

Education, Training & Certifications


Cleveland State University · 2014 Ph.D.
The Ohio State University, College of Medicine · 2009 M.S.